Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Joseph M. Mrus"'
Autor:
Anthony M. Mills, Laurence Brunet, Jennifer S. Fusco, Michael B. Wohlfeiler, Cindy P. Garris, Alan K. Oglesby, Joseph M. Mrus, Philip C. Lackey, Gregory P. Fusco
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 1, Pp 41-52 (2019)
Abstract Introduction Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy (ART), and a need exists to compare their clinical effectiveness, as defined by virolog
Externí odkaz:
https://doaj.org/article/776bda721e7f4713a0838d8a28b00c64
Autor:
Shelly Dhir, David J. Riedel, James Pike, Katie Mycock, J. Roberts, Alan Oglesby, Bonnie Collins, Moti Ramgopal, Megan Dominguez, Joseph M. Mrus, Douglas J. Ward, John Waller, Cindy Garris
Publikováno v:
AIDS Research and Treatment
AIDS Research and Treatment, Vol 2020 (2020)
AIDS Research and Treatment, Vol 2020 (2020)
Background. Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, literature on physician drivers for prescribing DTG 2DR is sparse. This study evaluated tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e8074baa66fd5037d0b8ee333131a0
https://doi.org/10.1155/2020/5923256
https://doi.org/10.1155/2020/5923256
Autor:
David A. Margolis, Conn M. Harrington, Krischan J Hudson, Christine L. Talarico, Pedro Cahn, Simon Vanveggel, Fritz Bredeek, Gary Richmond, Wim Louis Julien Parys, Jenny Huang, Giuliano Rizzardini, Herta Crauwels, Vadim Pokrovsky, Parul Patel, Peter Williams, Joseph M. Mrus, Jaime-Federico Andrade-Villanueva, Graham H R Smith, Susan Swindells, Susan L. Ford, Yeon Sook Kim, Gulam H Latiff, Kimberly Y. Smith, Axel Baumgarten, Mar Masiá, Vasiliki Chounta, William Spreen
Publikováno v:
New England Journal of Medicine. 382:1112-1123
Background Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. Methods In this phase ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68dcd06091be99a5f6d22eac2bc73d2b
https://doi.org/10.1056/nejmoa1904398
https://doi.org/10.1056/nejmoa1904398
Autor:
Alan Oglesby, Jennifer S Fusco, Cindy Garris, Gregory Fusco, Joseph M. Mrus, Michael Wohlfeiler, Philip Lackey, Laurence Brunet, Anthony Mills
Publikováno v:
Infectious Diseases and Therapy, Vol 9, Iss 1, Pp 41-52 (2019)
Infectious Diseases and Therapy
Infectious Diseases and Therapy
Introduction Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy (ART), and a need exists to compare their clinical effectiveness, as defined by virologic failur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6536ce4d66f06c6703733b5dcf635b12
https://doi.org/10.1007/s40121-019-00274-5
https://doi.org/10.1007/s40121-019-00274-5
Autor:
Anthony Mills, Federico Pulido, Joseph M. Mrus, William Spreen, David Dorey, Viviam Canon, Moti Ramgopal, David A. Margolis, Sandy Griffith, Miranda Murray, Hans Jaeger, Roger LeBlanc
Publikováno v:
HIV Research & Clinical Practice. 20:111-122
Background: Long-acting (LA) injectable antiretroviral therapy (ART) is a novel modality currently under development as an alternative to daily oral ART.Objective: The LATTE-2 study (ClinicalTrials...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a05a2a2dffa26cb8e3e9076d6cc891e
https://doi.org/10.1080/25787489.2019.1661696
https://doi.org/10.1080/25787489.2019.1661696
Autor:
Jaime Andrade-Villanueva, Amy Cutrell, Joseph M. Mrus, Veerle Van Eygen, William Spreen, Axel Baumgarten, Edgar T. Overton, Mar Masiá, Angela Wills, Susan L. Ford, Sterling Wu, Ken Chow, Giuliano Rizzardini, Vadim Pokrovsky, Keikawus Arastéh, Gulam H Latiff, Chloe Orkin, Sandy Griffith, Ronald D'Amico, Rodica Van Solingen-Ristea, Conn M. Harrington, Herta Crauwels, Shinichi Oka, Christine L. Talarico, Jeremy Roberts, Gary Richmond, Krischan J Hudson, Miguel de Górgolas Hernández-Mora, Susan Swindells, Kimberly Y. Smith, David A. Margolis, Marty St. Clair, Parul Patel, Simon Vanveggel, Pierre Marie Girard, Nicola Walters
Publikováno v:
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Journal of Acquired Immune Deficiency Syndromes (1999)
instname
Journal of Acquired Immune Deficiency Syndromes (1999)
HIV remains a major global health concern, with the Joint United Nations Programme on HIV/AIDS and the World Health Organization (WHO) estimating the number of people living with HIV (PLWH) to be ∼37.9 million in 2018.1,2 Improvements in HIV treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d982fc10553dbbfcbcd25d10d307cb
http://hdl.handle.net/10486/697840
http://hdl.handle.net/10486/697840
Autor:
Faith E. Fletcher, Janna Radtchenko, Richard Elion, Keith M Rawlings, Alan Oglesby, Joseph M. Mrus, Julie Priest, Moti Rampogal, Joseph J. Eron
Publikováno v:
Open Forum Infectious Diseases
Background This study evaluated differences in viral suppression by race and region among PLWH in care at 10 community practices. Methods PLWH (≥18 yrs) starting a new ART between Jan’15-Sept’19 with viral load at regimen prescription (Rx) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1366b570755ebeee26b43836ff61273
http://europepmc.org/articles/PMC7777964
http://europepmc.org/articles/PMC7777964
Autor:
Sandy Griffith, David Dorey, Conn M. Harrington, Paula Teichner, Mark S Shaefer, David A. Margolis, Peter Williams, Joseph W. Polli, Amy Cutrell, Ronald D'Amico, Rodica Van Solingen-Ristea, Krischan J Hudson, Joseph M. Mrus, Jenny Huang, William Spreen
Publikováno v:
Open Forum Infectious Diseases
Background Cabotegravir (CAB) and rilpivirine (RPV) are under development as a novel long-acting (LA) regimen for maintenance of HIV virologic suppression. Pooled Week 48 data from pivotal Phase 3 trials demonstrated noninferiority of CAB LA + RPV LA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6eebc96423d50ccc7ae4e54f95257f8d
http://europepmc.org/articles/PMC6809202
http://europepmc.org/articles/PMC6809202
Autor:
Setareh Seyedkazemi, Joseph M. Mrus, Dawn Averitt Bridge, Robert Ryan, Yaswant K. Dayaram, Kathleen Squires, Judith Feinberg, Judith S. Currier
Publikováno v:
AIDS Patient Care and STDs. 27:352-362
The Gender, Race And Clinical Experience (GRACE) study was conducted between October 2006 and December 2008 to evaluate sex- and race-based differences in outcomes after treatment with a darunavir/ritonavir-based antiretroviral regimen. Between June
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64c003d26656e6e2a615bb504b404ae0
https://doi.org/10.1089/apc.2013.0015
https://doi.org/10.1089/apc.2013.0015
Autor:
Judith S. Currier, Princy Kumar, Ron Falcon, Kathleen Squires, Kimberly Y. Smith, Joseph M. Mrus, Fernando Garcia, Robert Ryan
Publikováno v:
Journal of the National Medical Association. 104:366-376
The Gender, Race, and Clinical Experience (GRACE) study was designed to assess sex-based differences in darunavir/ ritonavir-based therapy and to enroll a female population representative of the racial demographics of women with human immunodeficienc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a13b08c953a089569051624244b30c9d
https://doi.org/10.1016/s0027-9684(15)30179-6
https://doi.org/10.1016/s0027-9684(15)30179-6